Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033 PHASE4 TERMINATED Results posted

The main objective of this study is to determine the time interval following the last treatment dose of enoxaparin at which the amount of anti-Xa level activity is reliably less than 0.2 international unit per milliliter (IU/mL) in patients presenting for elective surgery.

Details

Lead sponsor	Wake Forest University Health Sciences
Phase	PHASE4
Status	TERMINATED
Enrolment	122
Start date	Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Anticoagulants and Bleeding Disorders
• Surgery
• Regional Anesthesia Morbidity

Interventions

• Enoxaparin
• Enoxaparin

Countries

United States